Earnings summaries and quarterly performance for InspireMD.
Executive leadership at InspireMD.
Marvin Slosman
Detailed
President and Chief Executive Officer
CEO
AT
Andrea Tommasoli
Detailed
Chief Operating Officer
ML
Michael Lawless
Detailed
Chief Financial Officer
PV
Patrick Verta
Detailed
Executive Vice President of Clinical and Medical Affairs
PL
Pete Ligotti
Detailed
Executive Vice President, General Manager of U.S.
SG
Shane Gleason
Detailed
Chief Commercial Officer
Board of directors at InspireMD.
Research analysts who have asked questions during InspireMD earnings calls.
Recent press releases and 8-K filings for NSPR.
InspireMD Announces C-GUARDIANS Pivotal Trial Publication in JACC
NSPR
Product Launch
New Projects/Investments
- InspireMD announced the publication of results from its C-GUARDIANS pivotal trial in the Journal of the American College of Cardiology (JACC).
- The trial evaluated the safety and efficacy of the CGuard® Prime carotid stent system for the prevention of stroke in patients with asymptomatic carotid stenosis.
- C-GUARDIANS demonstrated a 30-day disabling stroke or myocardial infarction (DSMI) rate of 0.95% and a one-year ipsilateral stroke rate of 1.93%, which are the lowest reported in high-risk patients.
- The CGuard® Prime is FDA PMA-approved for the treatment of carotid artery stenosis in the United States.
- This publication is expected to accelerate efforts to bring CGuard® Prime to U.S. patients and drive adoption.
Jan 12, 2026, 2:00 PM
InspireMD Discusses CREST-2 Impact and Commercial Launch at Piper Sandler Conference
NSPR
Guidance Update
Product Launch
New Projects/Investments
- The recent CREST-2 trial data showed a statistically significant benefit for intervention (TFCAS) over medical management, which is expected to accelerate the shift to endovascular procedures for carotid artery disease and expand the overall market.
- InspireMD's CGuard stent, a second-generation closed-cell stent, demonstrated superior acute results in its C-GUARDIANS trial with a 0.95% event rate (death and stroke) compared to 1.3% in CREST-2, despite treating more complex patients.
- For Q4 2025, InspireMD anticipates global revenue to be at the higher end of its $2.5 million to $3.0 million guidance, building on a record international quarter of $2.0 million and $500,000 from the early U.S. commercial launch in Q3 2025.
- The company is progressing with its pipeline, targeting FDA approval in the first half of 2026 for the C-GUARDIANS 2 trial (integrating CGuard with Boston Scientific's Enroute device) and 510(k) clearance in the first half of 2027 for the C-GUARDIANS 3 (SwitchGuard) neuroprotection system.
Dec 3, 2025, 5:30 PM
InspireMD Discusses CREST-2 Trial Impact, Commercial Launch, and Pipeline Progress
NSPR
Product Launch
Guidance Update
New Projects/Investments
- The recent CREST-2 trial data was favorable for intervention, specifically TFCAS, showing a statistically significant benefit over medical management, which is expected to accelerate the shift to endovascular procedures and bring more patients into treatment.
- InspireMD's CGuard stent was included in the CREST-2 trial for approximately 4% of patients in the stent arm and has demonstrated superior results compared to older generation stents in meta-analyses. The company aims to differentiate CGuard from a general "class effect" of carotid artery stenting (CAS).
- InspireMD received FDA approval for its device in the U.S. around July 2025. As of the Q3 earnings call, over 100 patients had been treated in the commercial launch. The company provided Q4 global revenue guidance of $2.5-$3.0 million, anticipating reaching the higher end of this range. Q3 revenue was $2.5 million, with $2.0 million from international sales and $500,000 from the U.S. launch.
- The C-GUARDIANS 2 trial, integrating the CGuard stent into Boston's Enroute neuroprotection device, is progressing well, with FDA approval submission targeted for the first half of 2026. The C-GUARDIANS-3 study for the SwitchGuard neuroprotection system is planned to initiate enrollment right after Q1 2026, with 510(k) clearance targeted for the first half of 2027.
Dec 3, 2025, 5:30 PM
InspireMD Reports Q3 2025 Financial Results and CGuard Prime U.S. Commercial Launch
NSPR
Earnings
Product Launch
Revenue Acceleration/Inflection
- InspireMD reported total revenue of $2.5 million for Q3 2025, marking a 39% increase compared to the same period last year, primarily driven by the initial U.S. commercial launch of its CGuard Prime carotid stent system, which contributed $497,000 in U.S. revenue.
- The company recorded a net loss of $12.7 million, or $0.17 per basic and diluted share, for the third quarter ended September 30, 2025.
- As of September 30, 2025, cash and cash equivalents and marketable securities totaled $63.4 million, up from $34.6 million at December 31, 2024.
- Key operational highlights include the initiation of the U.S. commercial launch of the CGuard Prime system and the completion of over 100 U.S. carotid procedures.
Nov 4, 2025, 9:06 PM
InspireMD Reports Q3 2025 Revenue Growth Driven by CGuard Prime U.S. Launch
NSPR
Earnings
Product Launch
Revenue Acceleration/Inflection
- InspireMD reported Q3 2025 total revenue of $2.5 million, representing 39% year-over-year growth and over 40% sequential growth, primarily driven by the U.S. launch of CGuard Prime and continued international demand.
- The company achieved $497,000 in U.S. revenue in its first commercial quarter following FDA approval of CGuard Prime in late June, with over 100 cases completed and a strategic "modest premium" pricing approach.
- Gross profit increased over 100% to $864,000, with gross margin expanding to 34.2% in Q3 2025, attributed to higher revenue and a favorable shift towards higher-margin U.S. sales.
- InspireMD significantly strengthened its cash position to $63.4 million as of September 30, 2025, following $40.1 million from a PIPE offering and $17.9 million from warrant exercises.
- For Q4 2025, revenue is projected to be between $2.5 million and $3.0 million, anticipating sequential growth in U.S. sales and stable international demand.
Nov 4, 2025, 1:30 PM
InspireMD Announces Combined Financings of $58 Million
NSPR
New Projects/Investments
Product Launch
- InspireMD, Inc. (NSPR) has raised approximately $58 million in combined gross proceeds.
- This financing includes an equity private placement (PIPE) that generated $40.1 million and the exercise of warrants that generated $17.9 million.
- The warrant exercise was triggered by the U.S. Food and Drug Administration (FDA) premarket application approval (PMA) of the CGuard Prime carotid stent system.
- The company intends to use the net proceeds to fund operations, including sales and marketing and research and development, to support the U.S. launch of CGuard Prime.
Jul 31, 2025, 12:30 PM
InspireMD Launches CGuard Prime Carotid Stent System in U.S.
NSPR
Product Launch
New Projects/Investments
- InspireMD, Inc. (NSPR) announced the official commercial launch of its CGuard Prime carotid stent system in the U.S. on July 9, 2025, following FDA premarket application (PMA) approval.
- The CGuard Prime is a novel mesh-covered carotid stent designed to improve patient safety by minimizing early and late embolism risk for stroke prevention, utilizing a dual layer design with MicroNet™ and SmartFit™ technology.
- This U.S. launch represents a pivotal milestone for InspireMD, which has already secured double-digit market share for the CGuard Prime in over 30 countries globally.
Jul 9, 2025, 11:00 AM
InspireMD Discusses Impending FDA Approval and Market Opportunity for CGuard Stent
NSPR
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- InspireMD is focused on the impending FDA approval and commercialization of its next-generation CGuard carotid stent, with final details being submitted to the FDA.
- The U.S. market for carotid revascularization is estimated at just under $1 billion, significantly expanded by CMS coverage in October 2023 to include all standard risk patients for stenting procedures.
- The CGuard stent features a unique MicroNet mesh platform and has demonstrated strong clinical results, including a 30-day composite endpoint of death, stroke, and MI at 0.95% in a 316-patient pivotal trial.
- The company raised a $113 million funding round in May 2023 to support its commercial launch plan.
May 14, 2025, 5:16 PM
InspireMD Reports First Quarter 2025 Financial Results
NSPR
Earnings
Product Launch
Guidance Update
- InspireMD reported total revenue of $1,529,000 for the first quarter ended March 31, 2025, an increase of 1.2% compared to the same period in 2024, and a net loss of $11,166,000, or $0.22 per basic and diluted share.
- As of March 31, 2025, the company's cash and cash equivalents and marketable securities totaled $26,086,000, a decrease from $34,637,000 as of December 31, 2024.
- InspireMD is optimistic for anticipated FDA approval of its CGuard Prime carotid stent system in the third quarter of 2025.
- The company has advanced its commercial infrastructure and operational readiness in preparation for the anticipated U.S. launch of the CGuard Prime carotid stent system.
May 9, 2025, 11:00 AM
Quarterly earnings call transcripts for InspireMD.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more